Bachem Announces Changes to the Corporate Executive Committee
Rhea-AI Summary
Bachem (OTC: BCHMY) announced that Chief Commercial Officer Torsten Wöhr will leave the company and that CEO Anne-Kathrin Stoller will assume CCO duties in addition to her CEO role effective May 25, 2026. The company thanked Wöhr for his contributions to the oligonucleotide and peptide businesses and emphasized continuity in customer relationships during the transition.
Positive
- CEO to assume CCO duties from May 25, 2026 ensuring continuity
- Experienced leadership retained: Anne-Kathrin Stoller has prior CCO experience
- Customer relationship focus emphasized to preserve commercial momentum
Negative
- Interim dual role may concentrate responsibilities on one executive
- Successor pending creates temporary vacancy in dedicated commercial leadership
Bubendorf, Switzerland--(Newsfile Corp. - May 5, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) today announced that Torsten Wöhr, Chief Commercial Officer, has decided to pursue a new opportunity outside the company. Until a successor will be appointed, Anne-Kathrin Stoller will assume the role of Chief Commercial Officer in addition to her responsibilities as Chief Executive Officer (CEO), effective May 25, 2026.
“Torsten Wöhr has made a big contribution to the development and growth of Bachem over many years. During his tenure, he played an important role in building Bachem’s oligonucleotide business and in strengthening Bachem’s position as a global CMO player in the peptide market,” said Anne-Kathrin Stoller, CEO at Bachem. “I greatly valued our collaboration. Torsten helped shape our commercial organization and customer relationships. We thank him sincerely for his commitment and wish him every success in his future endeavors.”
Kuno Sommer, Chairman of the Board of Directors at Bachem, added: “Thanks to her many years of experience as Chief Commercial Officer, Anne will ensure a smooth transition and strong continuity in our customer relationships.”
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
For more information:
| Media Patrick Barth | Investors Barbora Blaha |
This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295942